Abiomed

Rank: 89
2016 Rank98
Employees747
Revenue:$329,543,000
R&D Spend:$49,759,000
Fiscal year ending:03-31-17
Click here to see all 100

Abiomed is a pioneer and global developer in healthcare technology and innovation, with a mission of RECOVERING HEARTS AND SAVING LIVES. Abiomed CEO, Chairman, and President, Michael R. Minogue, has focused the company’s efforts on developing ground-breaking technologies designed to assist or replace the life-sustaining pumping function of the failing heart. The Company’s portfolio of products and services offer healthcare professionals an array of choices across a broad clinical spectrum. From the world’s first total replacement heart to the World’s Smallest Heart Pump, 1/100th the size of the heart with rapid and simple insertion, Abiomed is dedicated to finding ways to bring the most advanced and beneficial technology to patients and physicians.

Abiomed Impella Devices Support 37,673 Patients, Enough to Fill Historic Fenway Park. Abiomed Impella® Therapy Receives FDA Approval for Cardiogenic Shock After Heart Attack or Heart Surgery. Abiomed Announces FDA Submission of Impella 2.5, Impella CP & Impella 5.0/LD Pre-Market Approval Supplements. Abiomed Announces Corporate Partnership With Fenway Park; Brings Impella Mobile Learning Lab to Historic Stadium. Abiomed Receives FDA HDE Approval for the Impella RP.

Big 100 Mini Logo Key Personnel: Michael Minogue, CEO, president & chairman; Dr. Seth Bilazarian, chief medical officer; Kelly Boucher, VP, HR; William Bolt, SVP, global product operations; Andrew Greenfield, VP & GM, marketing; Michael Howley, VP & GM, global sales; Steve McEvoy, VP, general counsel; Dr. Thorsten Siess, CTO; Michael Tomsicek, CFO; Dr. David Weber, COO;

22 Cherry Hill Drive
Danvers, MA
1923